DMP 777
Modify Date: 2024-01-11 06:47:34
DMP 777 structure
|
Common Name | DMP 777 | ||
|---|---|---|---|---|
| CAS Number | 157341-41-8 | Molecular Weight | 564.67200 | |
| Density | 1.227g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C31H40N4O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DMP 777DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor. |
| Name | (2S)-N-[(1R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-(4-methylpiperazine-1-carbonyl)phenoxy]-4-oxoazetidine-1-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor. |
|---|---|
| Related Catalog | |
| In Vivo | DMP-777-treated rats show a marked decrease in H/K-ATPase staining parietal cells. DMP-777-induced loss of parietal cells is significantly ameliorated with coadministration of omeprazole. DMP-777-treated animals demonstrates marked foveolar hyperplasia in the fundus with prominent expansion of diastase-resistant, PAS-positive surface mucous cells. When DMP-777 is coadministeredwith omprazole, there is a significant decrease in BrdUpositive S-phase cells compared with rats thatreceive DMP-777 alone[1]. After oral dosing of monkeys at 40 mg/kg with DMP-777 the only stereoisomer detected in the post-dose plasma samples is the starting material DMP-777, and no inversion of the configuration at positions 'a' and 'b' of DMP-777 has occurred in vivo[2]. Mist1-/- mice treated with DMP-777 show fewer chief cell to SPEM transitions. Mist1-/- mice treated with L635 demonstrates significantly fewer proliferative SPEM cells compared to control mice[3]. |
| Animal Admin | Groups 1A and 1B receive control vehicle instead of omeprazole and DMP-777. Group 2A and 2B are dosed with DMP-777 once daily on Study Day 3 or Days 3 and 4, respectively, and receive control vehicle instead of omeprazole. Groups 3A and 3B are treated with omeprazole twice daily on Study Days 1 to 3 or Days 1 to 4, respectively, and receive control vehicle instead of DMP-777. Groups 4A and 4B are dosed with both omeprazole and DMP-777. On Study Days 1 and 2, animals are pretreated with omeprazole twice daily, the dosing intervals separated by approximately 6 hr. On Study Day 3 (Group 4A) or Days 3 and 4 (Group 4B), omeprazole is coadministered with DMP-777. The first dose of omeprazole is administered approximately 1 hr prior to the dose of DMP-777. The second dose is approximately 6 hr after the last dose of DMP-777. Groups 1A, 2A, 3A, and 4A are sacrificed on Day 4. Groups 1B, 2B, 3B, and 4B are sacrificed on Day 5. Bromodeoxyuridine (BrdU) is administered by intraperitoneal injection to all the rats, 2 hr prior to necropsy. |
| References |
| Density | 1.227g/cm3 |
|---|---|
| Molecular Formula | C31H40N4O6 |
| Molecular Weight | 564.67200 |
| Exact Mass | 564.29500 |
| PSA | 100.65000 |
| LogP | 4.61200 |
| Index of Refraction | 1.581 |
| Storage condition | 2-8℃ |
![5-[(1R)-1-isocyanatobutyl]-1,3-benzodioxole Structure](https://www.chemsrc.com/caspic/397/181481-55-0.png)
CAS#:181481-55-0![(4S)-3,3-diethyl-4-[4-(4-methylpiperazine-1-carbonyl)phenoxy]azetidin-2-one Structure](https://www.chemsrc.com/caspic/445/181481-54-9.png)
CAS#:181481-54-9
CAS#:63740-97-6
CAS#:109-01-3
CAS#:142935-44-2
CAS#:120-57-0![(R)-1-(BENZO[D][1,3]DIOXOL-5-YL)BUTAN-1-AMINE Structure](https://www.chemsrc.com/caspic/314/181481-62-9.png)
CAS#:181481-62-9
CAS#:94-18-8| AZD5904 |
| N-(1-(2H-benzo[d]1,3-dioxolen-5-yl)-(1R)-butyl)((4S)-3,3-diethyl-4-{4-[(4-methylpiperazinyl)carbonyl]phenoxy}-2-oxoazetidinyl)carboxamide |
| L-694,458 |
| DMP777 |
| (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide |
| [S-(R*,S*)]-2-[4-[[(4-methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4-methylene-dioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide |
| DMP 777 |